Bet-at-home recently published its final FY25 figures.
* 2026 now also clouded by uncertainty * '26e-'27e EBIT down 12-4%; ~60% EBIT CAGR '25-'28e * 20-11x...
* +9% organic growth y-o-y, +1% vs. ABGSCe * 19% adj.
Revenue amounted to EUR 65.7m and was 2% below our estimate.
Solteq reported a weak Q1, with both revenue and earnings below estimates.
YIT’s Q1 results were well in line with expectations on an operative level, although one-offs clearl...
We hosted tonies at our Madrid conference. The key takeways fully underpin our positive view on the ...
* Q1 sales 11% lower than ABGSCe SEK 43m * Improved gross profit, likely due to favourable mix * Lik...
Redeye updates its view on Hacksaw following stronger-than-expected Q1 results, driven by operationa...
* Sales +4% and adj. EBITA -26% vs. consensus * Consensus EBITA estimates likely down by high single...
* EEs +7%, sales +8%, adj. EBIT +53% vs. ABGSCe * Stronger EBIT driven by series production and mild...
* Sales SEK 12.7m (vs. ABGSCe 7.8m), positive one-off effect of 4.
Redeye’s initial take on Sleeps Cycles' Q1 report confirms the company remains on track with its 202...
Gofore reported continued good sales momentum in March and the Q1 organic sales growth improved to 2...
Redeye provides its initial take on MedCap’s Q1 2026 report, which came in broadly in line with our ...
Besqab's Q1 looks solid to us. While the absence of housing starts (as expected) drove lower-than-ex...
Genovis delivered a Q1 broadly in line with our projections, 17% organic growth and 28% EBITDA margi...
* Q1 EBITDA NOK 10m vs ABGSCe NOK 4m * Pricer transition temporary drag, offset by Vusion momentum *...
Redeye updates its estimates and valuation after Lifco’s Q1 2026 report.
Redeye comments on SSH's Q1 2026 report, which was broadly in line on revenue but softer than expect...
